Asia Pacific Left Atrial Appendage (LAA) Closure Device Market Size, Share & Industry Trends Analysis Report By Application, By End User (Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology), By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Left Atrial Appendage (LAA) Closure Device Market
Market Report Description
The Asia Pacific Left Atrial Appendage (LAA) Closure Device Market would witness market growth of 20.5% CAGR during the forecast period (2022-2028).
As with any surgical operation, the therapist or surgeon would inform patients of any potential risks and problems. These therapies will be reserved for patients whose risk for the procedure is lower than their risk of stroke or hemorrhage if the operation is not performed. The LARIAT operation requires catheters to be guided through the blood arteries to the left atrial appendage of the heart.
The catheters are used to strengthen the loop around the left atrial appendage's opening, thus separating it from the rest of the heart. A catheter delivers the umbrella-shaped WATCHMAN gadget to the heart. Once the catheter is positioned at the left atrial appendage's entrance, the WATCHMAN is installed in the LAA to prevent blood from accessing the LAA. Although formed differently, the AMPLATZER Cardiac Plug is implanted similarly to the WATCHMAN, likewise to restrict blood flow into the LAA.
In certain instances, the medical staff may consider removing the left atrial appendage. This needs open-heart surgery and is typically performed in conjunction with other procedures, like coronary bypass surgery and valve surgery. Atrial fibrillation (AF) is one of the most prevalent arrhythmias, affecting the majority of the population all over the world. Significant mortality and morbidity including stroke and heart failure, are associated with atrial fibrillation.
One of the major factors boosting the growth of the regional left atrial appendage closure devices market in the region is the increasing geriatric population. According to the World Health Organization's 2011 Census, India has 104 million elderly people (those aged 60 and above), accounting for 8.6% of the overall population, it is anticipated that by 2030, 34 countries will have over 20% of their population aged 65 or older. However, with a rise in the regional geriatric population, the instances of atrial fibrillation are estimated to rise and this factor is propelling the growth of the regional market.
The China market dominated the Asia Pacific Left Atrial Appendage (LAA) Closure Device Market by Country in 2021; thereby, achieving a market value of $300.1 million by 2028. The Japan market is anticipated to grow at a CAGR of 19.8% during (2022 - 2028). Additionally, The India market would otain a CAGR of 21.2% during (2022 - 2028).
Based on Application, the market is segmented into Geospatial Mapping, Disaster Management, Energy & Resource Management, Surveillance & Monitoring, and Others. Based on End User, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Johnson & Johnson (Johnson & Johnson Services, Inc.), Occlutech Holding AG, LifeTech Scientific Corporation, Cardia, Inc. and Lepu Medical Technology Co., Ltd
Scope of the Study
Market Segments Covered in the Report:
- Ambulatory Surgery Centers
- Endocardial LAA Devices
- Epicardial LAA Devices
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Occlutech Holding AG
- LifeTech Scientific Corporation
- Cardia, Inc.
- Lepu Medical Technology Co., Ltd
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free